
==== Front
Int J Mol Med
Int J Mol Med
IJMM
International Journal of Molecular Medicine
1107-3756
1791-244X
D.A. Spandidos

39301632
10.3892/ijmm.2024.5424
ijmm-54-05-05424
Review
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)
Katoh Masuko 1
Katoh Masaru 12
1 Department of Global Network, M & M Precision Medicine, Tokyo 113-0033, Japan
2 Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan
Correspondence to: Dr Masaru Katoh, Department of Omics Network, National Cancer Center, 5-1-1 Tsukiji, Chuo, Tokyo 104-0045, Japan, E-mail: mkatoh-kkr@umin.ac.jp
11 2024
13 9 2024
13 9 2024
54 5 10024 7 2024
04 9 2024
Copyright: © 2024 Katoh et al.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
The 24 claudin (CLDN) genes in the human genome encode 26 representative CLDN family proteins. CLDNs are tetraspan-transmembrane proteins at tight junctions. Because several CLDN isoforms, such as CLDN6 and CLDN18.2, are specifically upregulated in human cancer, CLDN-targeting monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells have been developed. In the present review, CLDN1-, 4-, 6- and 18.2-targeting investigational drugs in clinical trials are discussed. CLDN18.2-directed therapy for patients with gastric and other types of cancer is the most advanced area in this field. The mouse/human chimeric anti-CLDN18.2 mAb zolbetuximab has a single-agent objective response rate (ORR) of 9%, and increases progression-free and overall survival in combination with chemotherapy. The human/humanized anti-CLDN18.2 mAb osemitamab, and ADCs AZD0901, IBI343 and LM-302, with single-agent ORRs of 28-60%, have been tested in phase III clinical trials. In addition, bsAbs, CAR T cells and their derivatives targeting CLDN4, 6 or 18.2 are in phase I and/or II clinical trials. AZD0901, IBI343, zolbetuximab and the anti-CLDN1 mAb ALE.C04 have been granted fast track designation or priority review designation by the US Food and Drug Administration.

Key words

epithelial-mesenchymal transition
fibroblast growth factor receptor
intratumor heterogeneity
immunosuppressive tumor microenvironment
non-small cell lung cancer
ovarian cancer
pancreatic cancer
splicing variant
TGF-β
WNT
Katoh Fund for Knowledge-Base and the Global Network ProjectsThe present study was supported by the Katoh Fund for Knowledge-Base and the Global Network Projects.
==== Body
pmc1. Introduction

The human claudin (CLDN) gene family consists of the CLDN1-12, 14-20, 22-25 and 34 genes (1-4). The CLDN10 gene encodes the CLDN10a and CLDN10b isoforms, expressed under control of renal/uterine and ubiquitous promoters, respectively (5). The CLDN18 gene encodes CLDN18.1 and CLDN18.2 isoforms, expressed under the control of pulmonary and gastric promoters, respectively (6). Therefore, the 24 human CLDN genes encode 26 representative full-length CLDN proteins (Table I).

CLDN isoforms at intercellular tight junctions have four transmembrane domains. The first extracellular folding loop stabilizes the paracellular interface and the C-terminal cytoplasmic region interacts with the zona occludens 1 scaffold protein for the assembly of other tight junction proteins (7,8). CLDN proteins that form homo- and heterotypical as well as trans/cis complexes regulate paracellular barrier or permeability functions at endothelial, epidermal, gastrointestinal, renal and other interfaces to maintain organ and/or whole-body homeostasis (9-15). Tight junction functions are dynamically regulated by junctional CLDN isoforms that undergo antegrade transport from the Golgi apparatus to the plasma membrane, endocytosis to early endosomes, and sorting to recycling endosomes for trafficking back to the cell surface or late endosomes for lysosomal degradation (Fig. 1).

Germline mutations in human CLDN genes have been reported in patients with non-cancerous diseases (Table I). CLDN1 mutations are related to ichthyosis, leukocyte vacuoles, alopecia and sclerosing cholangitis syndrome (16). CLDN2 mutations are related to obstructive azoospermia with hypercalciuria and kidney stones syndrome (17). CLDN10 mutations are associated with hypohidrosis, electrolyte imbalance, lacrimal gland dysfunction, ichthyosis and xerostomia syndrome (18). CLDN9 and CLDN14 mutations are associated with non-syndromic deafness (19,20). CLDN16 and CLDN19 mutations are associated with familial hypermagnesemia (21,22). CLDN11 mutations are associated with hypomyelinating leukodystrophy (23).

Somatic CLDN18::Rho GTPase-activating protein (ARHGAP)6, CLDN18::ARHGAP10, CLDN18::ARHGAP26 and CLDN18::ARHGAP42 fusions are detected in 3-15% of gastric cancer cases (24,25). Furthermore, CLDN1 upregulation in head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC), CLDN4 and CLDN6 upregulation in ovarian and other types of cancer, and CLDN18.2 upregulation in gastric or gastroesophageal junction adenocarcinoma (GEA) and pancreatic ductal adenocarcinoma (PDAC; Fig. 2) have been reported (26-30).

Because CLDN proteins at non-junctional basolateral membranes in tumor cells are accessible targets for antibody-based therapeutic modalities irrespective of their oncogenic or tumor suppressive function and signaling, anti-CLDN monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs; including bispecific T cell engagers), as well as CLDN-directed chimeric antigen receptor (CAR) T cells, have been developed (29-34). Drugs targeting CLDN1, 4, 6 and 18.2 have entered clinical trials for the treatment of cancer (Table II) and some of them have proceeded to later-phase trials (Fig. 3). Information on CLDN-targeted therapeutics in clinical trials is reviewed subsequently.

2. CLDN1-targeted therapy

CLDN1 is transcriptionally upregulated by tumor necrosis factor α signaling to the NF-κB complex, hypoxia signaling to the hypoxia-inducible factor α and β complex and WNT signaling to the β-catenin-T cell factor/lymphoid enhancer factor complex (30,35,36). Because CLDN1 upregulation in HCC maintains cancer stem cells and the protumor immune microenvironment and promotes invasion and metastasis, the prognosis of patients with CLDN1-high HCC is worse than that of patients with CLDN1-low HCC (30). CLDN1 is also upregulated in HNSCC and other types of cancer, such as breast, colorectal, gastric, ovarian, pancreatic and thyroid cancer (37-40).

Anti-CLDN1 mAbs

Humanized anti-CLDN1 mAb derived from a rat anti-human CLDN1 mAb (OM-7D3-B3) exhibits preclinical antitumor activity through the suppression of cancer stemness and tumor invasion and reprogramming of the immunosuppressive tumor microenvironment in HCC xenograft models, especially those with WNT/β-catenin signaling activation and an epithelial-mesenchymal transition phenotype (30,37).

The humanized anti-CLDN1 mAb ALE.C04 has also been shown to have preclinical antitumor activity as a single agent and in combination with immune checkpoint inhibitors in HNSCC xenograft models via perturbation of interactions between tumor and stromal cells to reverse extracellular matrix remodeling, tissue fibrosis and T cell immune evasion (40,41).

ALE.C04 has received fast track designation by the US Food and Drug Administration (FDA) for treatment of recurrent or metastatic CLDN1-positive HNSCC (42). A phase I/II clinical trial of ALE.C04, as a monotherapy and in combination with pembrolizumab, is ongoing, with an estimated completion date of February 2028 [trial no. National Clinical Trial (NCT)06054477; Table II].

3. CLDN4-targeted therapy

CLDN4 is upregulated in solid tumors, including triple-negative breast cancer (TNBC), colorectal and gastric cancer (intestinal subtype), non-small cell lung cancer (NSCLC), ovarian (serous subtype), pancreatic and prostate cancer, and urothelial carcinoma (26,40,43). The biological roles of CLDN4 in human carcinogenesis are dependent on the tumor type (26,39).

Anti-CLDN4 bsAbs

The bsAb ASP1002, which targets CLDN4 and 4-1BB, has been shown to induce antitumor activity in cancer with CLDN4 upregulation through costimulatory T cell signaling activation and subsequent T cell proliferation and cytokine production (43); however, to the best of our knowledge, single-chain variable fragment (scFv) components targeting CLDN4 and CD137 and their epitopes, in vitro functions and in vivo antitumor effects of ASP1002 are unknown. ASP1002 is in a phase I clinical trial for the treatment of CLDN4-positive solid tumors, such as colorectal, ovarian and prostate cancer, NSCLC, TNBC and urothelial carcinoma (trial no. NCT05719558; Table II).

4. CLDN6-targeted therapy

CLDN6 is preferentially expressed in pluripotent stem cells and endodermal precursors, such as hepatic or pancreatic progenitor cells, and in fetal tissue derived from the stomach, pancreas and lung, but is suppressed in adult tissues (44-46). CLDN6 is then reactivated in tumor tissue and upregulated in ovarian (14-55%), endometrial (17-21%) and gastric cancer (10-52%), HCC (0-80%), and NSCLC (6-11%), as well as rare malignancies, such as germ cell (54-100%) and atypical teratoid/rhabdoid tumors (29-100%), and myxofibrosarcomas (64%) (28,47-49).

Because CLDN6 is an oncofetal protein or cancer-specific antigen (28,44-49), CLDN6-targeting drugs have been developed for the treatment of cancer. Anti-CLDN6 mAbs (ASP1650) (50-52), ADCs (TORL-1-23) (53,54), CLDN6-targeting bsAbs (AMG 794, BNT142 and XmAb541) (55-57), trispecific antibodies (tsAbs; SAIL66) (58), and CAR T (BNT211) (45,59) and natural killer (NK) cells (60) have been tested in clinical trials (Table II).

Anti-CLDN6 mAbs

ASP1650 is a mouse/human chimeric anti-CLDN6 mAb that exhibited antitumor effects on ovarian cancer and testicular tumor cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity in a preclinical study (50) and has entered a phase I clinical trial for ovarian cancer (trial no. NCT02054351) and phase II clinical trial for male patients with germ cell tumors (trial no. NCT03760081). The objective response rates (ORRs) of ASP1650 were 2 (1/41) and 0% (0/13) in the NCT02054351 and NCT03760081 clinical trials, respectively (51,52).

Anti-CLDN6 ADCs

TORL-1-23 (CLDN6-23-ADC) is an anti-CLDN6 ADC that consists of humanized CLDN6-23-mAb that recognizes the second extracellular loop of CLDN6, a protease cleavable linker and a monomethyl auristatin E (MMAE) cytotoxic payload with a drug/antibody ratio (DAR) of 4.1 (53). In a preclinical study, TORL-1-23 was >10-fold more potent than CLDN6-23-mAb and exerted in vivo antitumor effects on bladder, endometrial and ovarian cancer (53). Notably, in a phase I clinical trial for the treatment of advanced cancer, including endometrial, ovarian and testicular cancer (trial no. NCT05103683), the ORR of TORL-1-23 in CLDN6-positive cancer was 32% (7/22) (54).

Anti-CLDN6 bsAbs

AMG 794, BNT142 and XmAb541 are bsAbs that simultaneously bind CLDN6 on tumor cells and CD3 on T cells for the elimination of tumor cells through recruitment, activation and proliferation of CLDN6-targeting cytotoxic T cells (55-57). Mouse model experiments have revealed that AMG 794 exerted antitumor effects on epithelial ovarian cancer and NSCLC (55) and that BNT142 exerted antitumor effects on serous ovarian cancer and ovarian teratocarcinoma (56). A phase I clinical trial of AMG 794 for patients with NSCLC, epithelial ovarian cancer and other types of solid tumor (trial no. NCT05317078), a phase I/II clinical trial of BNT142 for CLDN6-positive solid tumors (trial no. NCT05262530) and a phase I clinical trial of XmAb541 for solid tumors (trial no. NCT06276491) are ongoing.

Anti-CLDN6 tsAbs

SAIL66 is an anti-CLDN6 tsAb that binds CLDN6 on tumor cells and CD3, as well as 4-1BB on T cells to induce more robust immune reactions in CLDN6-positive tumor cells compared with conventional anti-CLDN6 bsAbs (58). In a preclinical study, SAIL66 successfully enhanced T cell infiltration and mitigated T cell exhaustion via potentiation of 4-1BB-mediated costimulatory signaling in syngeneic mouse model experiments (58). In a phase I clinical trial of SAIL66 for CLDN6-positive solid tumors, the anti-interleukin-6 receptor mAb tocilizumab was added to ameliorate cytokine release syndrome (CRS) caused by enhanced antitumor immunity (trial no. NCT05735366).

CLDN6-directed CAR T cells

BNT211 consists of CLDN6-targeting and 4-1BB-stimulating CAR T cells and a CAR T cell-amplifying RNA vaccine (CARVac) (59). CARVac is a liposomal CLDN6-expressing RNA that induces ectopic CLDN6 expression on antigen-presenting cells, such as dendritic cells and macrophages, for stimulation and expansion of CLDN6-targeting CAR T cells (59). BNT211 exerted antitumor effects on ovarian and lung tumors in a preclinical study (45) and was assessed in a phase I/II clinical trial for the treatment of patients with CLDN6-positive solid tumors (trial no. NCT04503278). Although signs of CRS appeared in ~50% of patients due to enhanced immunity, the ORR of BNT211 was 33% (7/21) (59).

5. CLDN18.2-targeted therapy

CLDN18.2 is upregulated in gastric (27-56%), esophageal (50%) and ovarian adenocarcinoma (10%), PDAC (30-60%), and NSCLC (4%) (27,61-64). Due to the upregulation of non-junctional CLDN18.2 in tumor tissues and the limited expression of tight junction protein CLDN18.2 in gastric epithelial cells, CLDN18.2 is a quasicancer-specific antigen (34). Currently, >20 drugs directed against CLDN18.2 are in clinical trials for treatment of GEA and other types of cancer (Table II).

Anti-CLDN18.2 mAbs

AB011 (65), ASKB589 (66,67), FG-M108 (68), MIL93 (69), osemitamab (70,71), ZL-1211 (72) and zolbetuximab (73-75) are representative anti-CLDN18.2 mAbs with ADCC activity that have entered clinical trials (Table II). ASKB589, FG-M108 and zolbetuximab have been investigated in phase III clinical trials, and a phase III clinical trial of osemitamab is underway (Fig. 3).

ASKB589, FG-M108 and osemitamab are humanized/human mAbs that had manageable safety profiles and were well-tolerated in early-phase clinical trials (trial nos. NCT04632108/NCT05632939, NCT04894825 and NCT04396821/NCT04495296, respectively). Notably, the single-agent ORR of ASKB589 in solid tumors was 22% (2/9) (66) and that of osemitamab was 58% (23/40) (70). The ORRs of ASKB589 + capecitabine and oxaliplatin (CAPOX) without or with anti-programmed cell death protein 1 (PD-1) mAb sintilimab in GEA were 75 (9/12) and 80% (12/15), respectively (66,67). The ORR of FG-M108 + nab-paclitaxel + gemcitabine in PDAC was 50% (7/14) (68) and the ORR of osemitamab + CAPOX + anti-PD-1 mAb nivolumab was 57% (45/79) in GEA (71). Currently, randomized, double-blind phase III clinical trials of ASKB589 + CAPOX + sintilimab vs. placebo + CAPOX + sintilimab (trial no. NCT06206733) and FG-M108 + CAPOX vs. placebo + CAPOX (trial no. NCT06177041) in first-line settings for CLDN18.2-positive GEA are ongoing. Osemitamab was granted orphan drug designation by the FDA and combination therapy of osemitamab + chemotherapy + nivolumab is advancing toward a phase III clinical trial for the treatment of GEA (trial no. NCT06093425).

Zolbetuximab is a mouse/human chimeric mAb with a single-agent ORR of 9% (4/43) in CLDN18.2-positive GEA (73). The combination of zolbetuximab + modified 5-fluorouracil, leucovorin and oxaliplatin chemotherapy (mFOLFOX6) resulted in greater clinical activity than placebo + mFOLFOX6 in the SPOTLIGHT study (trial no. NCT03504397) for GEA with CLDN18.2 upregulation. The median progression-free survival (mPFS) time was 10.6 vs. 8.7 months [hazard ratio (HR), 0.75; 95% CI, 0.60-0.94] and the median overall survival (mOS) time was 18.2 vs. 15.5 months (HR, 0.75; 95% CI, 0.60-0.94) (74). The combination of zolbetuximab + CAPOX improved clinical activity in comparison with placebo + CAPOX in the GLOW study (trial no. NCT03653507) (75). Zolbetuximab was granted priority review designation by the FDA in July 2023 but rejected due to unspecified deficiencies in a third-party manufacturing facility in January 2024 (76). The data were resubmitted to the FDA in May 2024 and decision is expected in November 2024 under the Prescription Drug User Fee Act (77).

Anti-CLDN18. 2 ADCs

ATG-022 (78), AZD0901 (CMG901) (79,80), EO-3021 (CPO102 or SYSA1801) (81), IBI343 (82), LM-302 (83,84) and SOT102 (85) are representative anti-CLDN18.2 ADCs in clinical trials (Table II). ATG-022, AZD0901, EO-3021 and LM-302 are human/humanized anti-CLDN18.2 mAbs conjugated with MMAE via cleavable linkers, whereas IBI343 and SOT102 are anti-CLDN18.2 ADCs connected to the topoisomerase I inhibitor exatecan and a derivative of PNU-159682 anthracycline, respectively (78-85). AZD0901 has been assessed in a phase III clinical trial, and IBI343 and LM-302 are entering phase III clinical trials (Fig. 3).

AZD0901, with a DAR of 4, has been shown to exert direct cytotoxic effects on CLDN18.2-overexpressing tumor cells and bystander killing effects on surrounding tumor cells in preclinical studies, and had a single-agent ORR of 44% (39/89) in GEA with CLDN18.2 upregulation in the KYM901 phase I clinical trial (trial no. NCT04805307) (79,80). AZD0901 also exhibited manageable safety profiles in the clinic. Anemia (62.8%), vomiting (57.5%) and hypoalbuminemia (57.5%) were common treatment-emergent adverse events (TEAEs), and decreased neutrophil count (18.6%) and anemia (13.3%) were the most frequent grade ≥3 TEAEs (79). AZD0901 monotherapy for treatment of CLDN18.2-overexpressing GEA was granted fast track designation by the FDA in April 2022 (86) and is currently in a phase II clinical trial with an expected completion date of May 2025 (trial no. NCT06219941); another phase III randomized clinical trial of AZD0901 monotherapy vs. apatinib, docetaxel, irinotecan, paclitaxel or TAS-102, has an expected completion date of April 2026 (trial no. NCT06346392).

IBI343 had single-agent ORRs of 28 [7/25 patients with PDAC and biliary tract cancer (BTC)] and 40% (4/10 patients with CLDN18.2-positive PDAC) in a phase I clinical trial (trial no. NCT05458219) and a manageable safety profile with any-grade [anemia (37%), nausea (26%), vomiting (26%) and decreased white blood cell count (20%)] and grade ≥3 treatment-related adverse events (TRAEs) [anemia (6%) and decreased white blood cell counts (3%)] (82). IBI343 monotherapy was granted fast track designation by the FDA for the treatment of PDAC (87). By contrast, for the treatment of GEA, a phase II clinical trial of combination therapy of IBI343 + sintilimab (trial no. NCT06321913) and a phase III randomized clinical trial of IBI343 vs. irinotecan or paclitaxel, (trial no. NCT06238843) are planned but not yet recruiting.

LM-302 had superior antitumor efficacy to zolbetuximab in a preclinical study using gastric cancer model (83), and a single-agent ORR of 31% (11/36) in CLDN18.2-positive GEA and a manageable safety profile in a phase I/II clinical trial (trial no. NCT05161390) (84). LM-302 is proceeding to a phase III randomized clinical trial of LM-302 vs. the investigator's choice of therapy, apatinib or irinotecan, for treatment of CLDN18.2-positive GEA (trial no. NCT06351020).

Anti-CLDN18.2 bsAbs

AZD5863 (88), givastomig (89), gresonitamab (90), IBI389 (91), PM1032 (92,93), PT886 (94), Q-1802 (95) and QLS31905 (96) are representative anti-CLDN18.2 bsAbs (Table II).

AZD5863, gresonitamab, IBI389 and QLS31905 simultaneously binds CLDN18.2 on tumor cells and CD3 on T cells (88,90,91,96), which activates CD3 signaling in T cells and redirects cytotoxic T cells toward tumor killing through lytic synapse formation and release of granzymes and perforins (97,98).

Givastomig, PM1032, PT886 and Q-1802 simultaneously bind CLDN18.2 and non-CD3 immune antigens; givastomig and PM1032 enhance antitumor immunity via 4-1BB-induced activation of costimulatory signaling (89,92); PT886 reactivates phagocytosis via CD47-dependent inhibition of 'do not eat me' signaling (94); and Q-1802 inhibits immune checkpoints via programmed death-ligand 1 (PD-L1)/PD-1 signaling blockade (95). Givastomig and PT886 have been granted orphan drug designation by the FDA (94,99).

Compared with anti-CLDN18.2 mAbs and ADCs, anti-CLDN18.2 bsAbs are in relatively early phases of clinical trials (88-96): Givastomig, IBI389 and Q-1802 are in phase I clinical trials; AZD5863, PM1032 and PT886 are in phase I/II clinical trials; and QLS31905 is proceeding to phase I/II clinical trials (Fig. 3).

In a phase I clinical trial, IBI389 caused any-grade TRAEs in 97.4% (111/114) and grade ≥3 TRAEs in 55.3%, including any-grade CRS (57.0%) and grade 3 CRS (0.9%), of patients with solid tumors, such as GEA (n=37) and PDAC (n=66) (trial no. NCT05164458). The single-agent ORR of IBI389 was 31% (8/26) in GEA with CLDN18.2 overexpression (91).

In a phase I/II clinical trial, PM1032 caused any-grade TRAEs in 73% (22/30) and grade ≥3 TRAEs in 10% of gastrointestinal cancer cases (trial no. NCT05839106). The single-agent ORR of PM1032 was 20% (2/10) in CLDN18.2-positive GEA (93).

In a phase I clinical trial (trial no. NCT04856150) of Q-1802, any-grade TRAEs, including nausea (62%; 18/29), vomiting (62%) and abdominal pain (28%), immune-related adverse events (AEs; such as abnormal thyroid function, rash and arthritis) (24%), and grade 3 TRAEs such as nausea and vomiting (24%) and grade 4 TRAE hyponatremia (3%) were observed. The single-agent ORR of Q-1802 was 22% (2/9) in gastrointestinal cancer (95).

QLS31905 treatment was associated with any-grade TRAEs in 98% (51/52) and grade ≥3 TRAEs in 40% of patients treated with 0.5-500.0 mg/kg once/week (qW) or once every 2 weeks (q2W) QLS31905, including grade 3 CRS in 2 patients in the 350 mg/kg qW QLS31905 cohort, in a phase I clinical trial (trial no. NCT05278832). The single-agent ORR of QLS31905 was 11% (3/27) in the phase I study (96), and a phase I/II clinical trial of QLS31905 plus chemotherapy is planned (trial no. NCT06041035).

CLDN18.2-directed CAR-T cells

Satricabtagene autoleucel (Satri-cel) refers to autologous CAR T cells targeting CLDN18.2: CAR T cells were generated from peripheral blood mononuclear cells via lentiviral transduction of a second-generation CAR construct consisting of an extracellular humanized anti-CLDN18.2 scFv and a CD8α hinge region, CD28 transmembrane domain and cytoplasmic CD28 costimulatory and CD3ζ signaling domains. CAR T cells were formulated and infused back following preconditioning combination therapy with cyclophosphamide, fludarabine and nab-paclitaxel or gemcitabine (100,101).

Satri-cel was assessed in a phase I clinical trial (trial no. NCT03874897) for the treatment of solid tumors on the basis of the results of a preclinical study that revealed antitumor effects with persistent infiltration of CAR T cells into CLDN18.2-positive gastric cancer patient-derived xenograft models (100). A total of ~75% of patients in the Satri-cel clinical trial received bridging therapy, such as folinic acid, fluorouracil and irinotecan, nab-paclitaxel or irinotecan, during autologous CAR T cell production (median, 27 days; range, 22-187 days) (101). Satri-cel exhibited tolerability and safety profiles with manageable AEs, such as preconditioning-associated transient hematological toxicity (grade ≥3, 100%), CRS (any grade, 97%; grade ≥3, 0%), nausea (any grade, 67%; grade ≥3, 1%), vomiting (any grade, 53%; grade ≥3, 3%) and gastric mucosal injury (grade 1/2, 7%; grade 3, 1%) and without immune effector cell-associated neurotoxicity syndrome, and clinical activity, as indicated by an ORR of 39% (38/98), mPFS time of 4.4 months (95% CI, 3.7-6.6) and mOS time of 8.8 months (95% CI, 7.1-10.2) (101). Currently, a randomized phase I/II clinical trial of Satri-cel vs. apatinib, irinotecan or paclitaxel, for the treatment of CLDN18.2-positive GEA and PDAC is ongoing (trial no. NCT04581473).

CLDN18.2-targeting CAR T cells, such as LB1908 expressing a CAR with a 4-1BB costimulatory domain (102), IMC002 harboring a CAR with anti-CLDN18.2 variable heavy domain of heavy chain antibody instead of a scFv (103), AZD6422-armed CAR T cells with a dominant-negative TGF-β type II receptor (dnTGFBR2) to overcome the TGF-β-induced immunosuppressive tumor microenvironment (104) and KD-496 bispecific CAR T cells that simultaneously recognize CLDN18.2 and NK group 2 member D (NKG2D) ligands on tumor cells (105), are also in phase I clinical trials for the treatment of patients with CLDN18.2-positive tumors (Table II).

6. Future research directions

CLDN-directed therapy poses issues related to antibody-based therapeutic modalities. Perspectives on mAbs, ADCs, bsAbs and CAR drugs are discussed subsequently, with a focus on CLDN targeting for cancer treatment.

mAbs

Phase III SPOTLIGHT and GLOW clinical trials for CLDN18.2-positive GEA demonstrated greater clinical activity of zolbetuximab + chemotherapy than placebo + chemotherapy (74,75). Other anti-CLDN18.2 mAbs have been assessed, and ASKB589, FG-M108 and osemitamab are being assessed in randomized phase III clinical trials with expected completion dates of December 2026, January 2027 and October 2025, respectively (Fig. 3). The single-agent ORR of chimeric mAb zolbetuximab is 9% (73), whereas that of humanized mAbs ASKB589 and osemitamab, which have increased affinity and enhanced ADCC effects, is 22 and 58%, respectively (66,70). Previous-generation mAb drugs were chimeric antibodies that elicit host immune responses to remaining variable regions derived from mouse antibody, while current-generation mAb drugs are human/humanized antibodies without mouse-derived variable regions (106). Comparison of the clinical activity (mPFS and mOS) of zolbetuximab and other humanized/human anti-CLDN18.2 mAbs is warranted.

ADCs

Anti-CLDN ADCs (78-85) are classified into two types. Most ADCs (CLDN6, TORL-1-23; CLDN18.2, ATG-022, AZD0901, EO-3021 and LM-302) include a human/humanized mAb, cleavable linker and an MMAE microtubule inhibitor. Others have cytotoxic DNA-damaging payloads (CLDN18.2, IBI343 and SOT102; Table II). In general, the clinical activity of these anti-CLDN ADCs is affected by mAb epitope affinity and modification, linker chemistry, and payload pharmacology (107,108).

CLDN-targeting ADCs have exhibited improved clinical outcomes over CLDN-targeting chimeric mAbs in early-phase clinical trials; the single-agent ORRs of ATG-022 (78), AZD0901 (79), EO-3021 (81), IBI343 (82), LM-302 (84) and TORL-1-23 (54) were 20, 44, 38, 28, 31 and 32%, respectively, compared with 0-9% for the chimeric anti-CLDN mAbs ASP1650 (51,52) and zolbetuximab (73).

ORRs of the aforementioned anti-CLDN ADCs are similar to those of FDA-approved ADCs targeting other tumor-associated antigens, such as the ORR of 31.5% of anti-trophoblast cell surface antigen 2 ADC sacituzumab govitecan (109) and the ORR of 42.9% of the anti-nectin cell adhesion molecule 4 ADC enfortumab vedotin (110). AZD0901, IBI343 and LM-302 have entered or are entering phase III clinical trials, which will yield mPFS and mOS data in the future.

bsAbs

Anti-CLDN bsAbs in phase I or I/II clinical trials (Table II) are classified into CD3-directed (CLDN6-targeting AMG 794, BNT142 and XmAb541; and CLDN18.2-targeting AZD5863, gresonitamab, IBI389 and QLS31905) and non-CD3-directed (CLDN4-targeting ASP1002; and CLDN18.2-targeting givastomig, PM1032, PT886 and Q-1802) (43,55-57,88-96). IBI389, PM1032, Q-1802 and QLS31905 have single-agent ORRs of 31, 20, 22 and 11%, respectively (91,93,95,96). A study on gresonitamab was terminated due to business decisions of Amgen (trial no. NCT04260191).

In clinical oncology, bsAbs such as amivantamab (targeting EGFR and MET) (111), petosemtamab (targeting EGFR and leucine-rich repeat-containing G-protein coupled receptor 5) (112) and zenocutuzumab (targeting human EGFR 2 and 3) (113) dually target tumor-specific antigens (97,98). Since upregulation of CLDN18.2 (56%) (27), EGFR (27%) (114), HER2 (21%) (115), fibroblast growth factor receptor 2 isoform b (4-5%) (116,117) and MET (24%) (118) in gastric cancer has been detected and mAbs targeting these receptor tyrosine kinases (RTKs) have been developed (111,112,119), bsAbs dually targeting CLDN18.2 and RTKs may serve as antibody-based drugs for the treatment of gastric cancer in the future.

CAR T or CAR-NK cells

Satri-cel, an autologous CAR T cell therapy with a second-generation CLDN18.2-directed CAR, has an ORR of 39% (101), which is similar to the ORRs of BNT211 (CLDN6-targeting CAR-T cell + RNA vaccine; 33%) (59) and other solid tumor-targeting CAR T cell therapies directed at carcinoembryonic antigen (15%; 6/40) (120), EGFR (18%; 2/11) (121), glypican 3 (50%; 11/22) (122) and guanylyl cyclase 2C (26%; 5/19) (123), but less effective than FDA-approved CAR T cell therapies targeting hematological malignancies, such as the CD19-directed CAR T cells axicabtagene ciloleucel (82%; 83/101) (124) and B cell maturation antigen-directed CAR T cells ciltacabtagene autoleucel (98%; 95/97) (125).

Numerous challenges hinder the activities of CAR T cells, especially those in solid tumors. These include epitope-losing subclonal replacement on the basis of pretreatment heterogeneity and/or posttreatment evolution (126-128), decreased infiltration of CAR T cells into an immunosuppressive tumor microenvironment harboring angiogenic endothelial cells, extracellular matrix-remodeling cancer-associated fibroblasts, regulatory T cells, M2-type macrophages and monocytic myeloid-derived suppressor cells (129-131), and decreased persistence of CAR T cells due to mechanisms similar to the exhaustion of effector T cells with diminished anti-tumor activity dependent on TGF-β signaling as well as PD-L1/PD-1 and other coinhibitory signaling (132-134).

bsCAR T cells dually targeting CLDN18.2 and NKG2D ligands have been developed to address intratumor heterogeneity (105). CLDN6-directed CAR-NK cells, which incorporate the NKG2D transmembrane domain, CD244 costimulatory domain and the DNAX-activation protein 10 signaling domain have been developed to enhance antitumor immunity (60). CLDN18.2-directed CAR T cells armed with dnTGFBR2 have been developed to eliminate immunosuppressive effects of TGF-β (104) and preclinical CAR T cells armed with forkhead-box O1 transcription factor have been developed to maintain the stem/memory cell subpopulation, retain effector functions and prevent the exhaustion phenotype (133,134). These strategies might further improve the clinical activity of CLDN-targeted CAR therapy.

7. Conclusion

Drugs directed at CLDN1, 4, 6 and 18.2 tumor-associated antigens have been developed on the basis of mAb, ADC, bsAb or CAR modalities. A total of >30 CLDN-targeting therapeutics have entered clinical trials, and anti-CLDN18.2 mAbs (ASKB589, FG-M108, osemitamab and zolbetuximab) and ADCs (AZD0901, IBI343 and LM-302) have been assessed in phase III clinical trials. AZD0901, IBI343, zolbetuximab and anti-CLDN1 mAb ALE.C04 have been granted fast track or priority review designation by the FDA but have not yet been approved as of August 2024. However, there is a lack of results from phase III clinical trials other than those involving zolbetuximab. Monotherapies with human/humanized ADCs and armed CAR T cells may be promising choices for CLDN-directed cancer therapy.

Acknowledgements

Not applicable.

Availability of data and materials

Not applicable.

Authors' contributions

MasukoK and MasaruK wrote the manuscript. Data authentication is not applicable. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Figure 1 CLDN proteins at tight junctions. CLDN isoforms consist of four transmembrane domains, an N-terminal cytoplasmic region, ECL1 and 2, an intracellular loop and a C-terminal cytoplasmic region. The WWCC motif in ECL1 folds β-strand structures and stabilizes the paracellular interface of CLDNs, whereas the C-terminal region that interacts with the ZO-1 scaffold protein connects CLDNs to actin filaments and recruits other tight junction proteins. CLDN proteins are dynamically regulated via anterograde transport from the Golgi apparatus to the plasma membrane, internalization into early endosomes and sorting to recycling or late endosomes. CLDN proteins regulate the paracellular barrier and permeability functions at endothelial, epidermal, gastrointestinal, renal and other interfaces to maintain organ and/or whole-body homeostasis. CLDN, claudin; ECL, extracellular loop; ZO, zona occludens; ?, not confirmed.

Figure 2 CLDN6 and CLDN18.2 upregulation in human cancer. CLDN, claudin.

Figure 3 Clinical CLDN-targeted therapy for cancer. A total of >30 drugs directed at CLDN1, 4, 6 or 18.2 on the basis of mAbs, ADCs, bsAbs and CAR cell modalities are currently being assessed in clinical trials for the treatment of cancer. Anti-CLDN18.2 (mAbs, ASKB589, FG-M108, osemitamab and zolbetuximab; ADCs, AZD0901, IBI343 and LM-302) have been tested in phase III clinical trials. bsAbs and CAR cells targeting CLDN4, 6 or 18.2 are in phase I and/or II clinical trials. Red denotes fast track designation or priority review designation by the US FDA. ADC, antibody-drug conjugate; bsAb, bispecific antibody; CAR, chimeric antigen receptor; CLDN, claudin; FDA, Food and Drug Administration; mAb, monoclonal antibody; Satri-cel, satricabtagene autoleucel.

Table I Human CLDN gene family.

Gene	Alias	Locus	Paracellular function	Disease (genetic alteration)	
CLDN1	SEMP1	3q28	Paracellular barrier	ILVASC syndrome (germline mut)	
CLDN2	-	Xq22.3	Cation channel	OAZON syndrome (germline mut)	
CLDN3	RVP1	7q11.23	Paracellular barrier	-	
CLDN4	CPETR1	7q11.23	Unclear	-	
CLDN5	TMVCF	22q11.21	Paracellular barrier	-	
CLDN6	-	16p13.3	Paracellular barrier	-	
CLDN7	-	17p13.1	Unclear	-	
CLDN8	-	21q22.11	Unclear	-	
CLDN9	DFNB116	16p13.3	Paracellular barrier	Non-syndromic deafness (germline mut)	
CLDN10 a	-	13q32.1	Anion channel (CLDN10a); cation channel (CLDN10b)	HELIX syndrome (germline mut)	
CLDN11	-	3q26.2	Unclear	HLD22 (germline mut)	
CLDN12	-	7q21.13	Unclear	-	
CLDN14	DFNB29	21q22.13	Paracellular barrier	Non-syndromic deafness (germline mut)	
CLDN15	-	7q22.1	Cation channel	-	
CLDN16	HOMG3	3q28	Cation channel	Familial hypomagnesemia (germline mut)	
CLDN17	-	21q21.3	Anion channel	-	
CLDN18 a	-	3q22.3	Paracellular barriers	Gastric cancer (somatic CLDN18::ARHGAP fus)	
CLDN19	HOMG5	1p34.2	Cation channel	Familial hypomagnesemia (germline mut)	
CLDN20	-	6q25.3	NR	-	
CLDN22	CLDN21	4q35.1	NR	-	
CLDN23	-	8p23.1	Paracellular barrier	-	
CLDN24	CLDN22	4q35.1	NR	-	
CLDN25	CLDN24	11q23.2	Cation channel	-	
CLDN34	-	Xp22.2	NR	-	
a Two isoforms depending on promoter. ARHGAP, Rho GTPase-activating protein; CLDN, claudin; fus, fusion; HELIX, hypohidrosis, electrolyte imbalance, lacrimal gland dysfunction, ichthyosis and xerostomia; HLD22, hypomyelinating leukodystrophy-22; ILVASC, ichthyosis, leukocyte vacuoles, alopecia and sclerosing cholangitis; mut, mutation; NR, not reported; OAZON, obstructive azoospermia with nephrolithiasis; -, not applicable.

Table II Clinical development of CLDN-targeting therapeutics.

Target/modality	Drug	Phase	Clinical trial ID	Design	Status	
CLDN1 mAb	ALE.C04a	I/II	NCT06054477	Mono and combo	Recruiting	
CLDN4 bsAb	ASP1002	I	NCT05719558	Mono	Recruiting	
CLDN6 mAb	ASP1650	II	NCT03760081	Mono	Completed	
CLDN6 ADC	TORL-1-23	I	NCT05103683	Mono	Recruiting	
CLDN6 bsAb	AMG 794	I	NCT05317078	Mono	Active NR	
BNT142	I/II	NCT05262530	Mono	Recruiting	
XmAb541	I	NCT06276491	Mono	Recruiting	
CLDN6 tsAb	SAIL66	I	NCT05735366	Mono	Recruiting	
CLDN6 CAR	BNT211	I/II	NCT04503278	Mono	Recruiting	
CAR NK cells	I	NCT05410717	Mono	Recruiting	
CLDN18.2 mAb	AB011	I	NCT04400383	Mono and combo	Completed	
ASKB589	III	NCT06206733	Combo	Recruiting	
FG-M108	III	NCT06177041	Combo	Recruiting	
MIL93	I	NCT04671875	Mono	Recruiting	
Osemitamabb	III	NCT06093425	Combo	NyR	
ZL-1211	I/II	NCT05065710	Mono	Completed	
Zolbetuximabc	III	NCT03504397	Combo	Active NR	
CLDN18.2 ADC	ATG-022b	I	NCT05718895	Mono	Recruiting	
AZD0901a	III	NCT06346392	Mono	Recruiting	
EO-3021	I	NCT05980416	Mono	Recruiting	
IBI343a	III	NCT06238843	Mono	Recruiting	
LM-302	III	NCT06351020	Mono	Recruiting	
SOT102	I/II	NCT05525286	Mono and combo	Recruiting	
CLDN18.2 bsAb	AZD5863	I/II	NCT06005493	Mono	Recruiting	
Givastomigb	I	NCT04900818	Mono	Recruiting	
Gresonitamab	I	NCT04260191	Mono	Terminated	
IBI389	I	NCT05164458	Mono and combo	Recruiting	
PM1032	I/II	NCT05839106	Mono	Recruiting	
PT886b	I/II	NCT05482893	Mono and combo	Recruiting	
Q-1802	I	NCT04856150	Mono	Recruiting	
QLS31905	I/II	NCT06041035	Combo	NyR	
CLDN18.2 CAR	AZD6422	I	NCT05981235	Mono	Recruiting	
IMC002	I	NCT05472857	Mono	Recruiting	
KD-496	I	NCT05583201	Mono	Recruiting	
LB1908	I	NCT05539430	Mono	Recruiting	
Satri-cel	I/II	NCT04581473	Mono	Recruiting	
a FDA fast track;

b FDA orphan drug;

c FDA priority review, rejected owing to unspecified deficiencies in a third-party manufacturing facility, but resubmitted. ADC, antibody-drug conjugate; bsAb, bispecific antibody; CAR, chimeric antigen receptor; CLDN, claudin; combo, combination therapy; FDA, Food and Drug Administration; mAb, monoclonal antibody; mono, monotherapy; NCT, National Clinical Trial; NK, natural killer; NR, not recruiting; NyR, not yet recruiting; Satri-cel, satricabtagene autoleucel; tsAb, trispecific antibody.
==== Refs
References

1 Tsukita S Furuse M Itoh M Multifunctional strands in tight junctions Nat Rev Mol Cell Biol 2 285 293 2001 10.1038/35067088 11283726
2 Katoh M Katoh M CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family Int J Mol Med 11 683 689 2003 12736707
3 Krause G Winkler L Mueller SL Haseloff RF Piontek J Blasig IE Structure and function of claudins Biochim Biophys Acta 1778 631 645 2008 10.1016/j.bbamem.2007.10.018 18036336
4 Baltzegar DA Reading BJ Brune ES Borski RJ Phylogenetic revision of the claudin gene family Mar Genomics 11 17 26 2013 10.1016/j.margen.2013.05.001 23726886
5 Günzel D Stuiver M Kausalya PJ Haisch L Krug SM Rosenthal R Meij IC Hunziker W Fromm M Müller D Claudin-10 exists in six alternatively spliced isoforms that exhibit distinct localization and function J Cell Sci 122 1507 1517 2009 10.1242/jcs.040113 19383724
6 Niimi T Nagashima K Ward JM Minoo P Zimonjic DB Popescu NC Kimura S Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing Mol Cell Biol 21 7380 7390 2001 10.1128/MCB.21.21.7380-7390.2001 11585919
7 Zihni C Mills C Matter K Balda MS Tight junctions: From simple barriers to multifunctional molecular gates Nat Rev Mol Cell Biol 17 564 580 2016 10.1038/nrm.2016.80 27353478
8 Vecchio AJ Rathnayake SS Stroud RM Structural basis for Clostridium perfringens enterotoxin targeting of claudins at tight junctions in mammalian gut Proc Natl Acad Sci USA 118 e2024651118 2021 10.1073/pnas.2024651118 33876770
9 Günzel D Yu AS Claudins and the modulation of tight junction permeability Physiol Rev 93 525 569 2013 10.1152/physrev.00019.2012 23589827
10 France MM Turner JR The mucosal barrier at a glance J Cell Sci 130 307 314 2017 10.1242/jcs.193482 28062847
11 Stamatovic SM Johnson AM Sladojevic N Keep RF Andjelkovic AV Endocytosis of tight junction proteins and the regulation of degradation and recycling Ann N Y Acad Sci 1397 54 65 2017 10.1111/nyas.13346 28415156
12 Horowitz A Chanez-Paredes SD Haest X Turner JR Paracellular permeability and tight junction regulation in gut health and disease Nat Rev Gastroenterol Hepatol 20 417 432 2023 10.1038/s41575-023-00766-3 37186118
13 Meoli L Günzel D The role of claudins in homeostasis Nat Rev Nephrol 19 587 603 2023 10.1038/s41581-023-00731-y 37344620
14 Tanaka H Yamamoto Y Kashihara H Yamazaki Y Tani K Fujiyoshi Y Mineta K Takeuchi K Tamura A Tsukita S Claudin-21 has a paracellular channel role at tight junctions Mol Cell Biol 36 954 964 2016 10.1128/MCB.00758-15 26729464
15 Raya-Sandino A Lozada-Soto KM Rajagopal N Garcia-Hernandez V Luissint AC Brazil JC Cui G Koval M Parkos CA Nangia S Nusrat A Claudin-23 reshapes epithelial tight junction architecture to regulate barrier function Nat Commun 14 6214 2023 10.1038/s41467-023-41999-9 37798277
16 Hadj-Rabia S Baala L Vabres P Hamel-Teillac D Jacquemin E Fabre M Lyonnet S De Prost Y Munnich A Hadchouel M Smahi A Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: A tight junction disease Gastroenterology 127 1386 1390 2004 10.1053/j.gastro.2004.07.022 15521008
17 Askari M Karamzadeh R Ansari-Pour N Karimi-Jafari MH Almadani N Sadighi Gilani MA Gourabi H Vosough Taghi Dizaj A Mohseni Meybodi A Sadeghi M Identification of a missense variant in CLDN2 in obstructive azoospermia J Hum Genet 64 1023 1032 2019 10.1038/s10038-019-0642-0 31320686
18 Klar J Piontek J Milatz S Tariq M Jameel M Breiderhoff T Schuster J Fatima A Asif M Sher M Altered paracellular cation permeability due to a rare CLDN10B variant causes anhidrosis and kidney damage PLoS Genet 13 e1006897 2017 10.1371/journal.pgen.1006897 28686597
19 Sineni CJ Yildirim-Baylan M Guo S Camarena V Wang G Tokgoz-Yilmaz S Duman D Bademci G Tekin M A truncating CLDN9 variant is associated with autosomal recessive nonsyndromic hearing loss Hum Genet 138 1071 1075 2019 10.1007/s00439-019-02037-1 31175426
20 Wilcox ER Burton QL Naz S Riazuddin S Smith TN Ploplis B Belyatseva I Ben-Yosef T Liburd NA Morell RJ Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29 Cell 104 165 172 2001 10.1016/S0092-8674(01)00200-8 11163249
21 Simon DB Lu Y Choate KA Velazquez H Al-Sabban E Praga M Casari G Bettinelli A Colussi G Rodriguez-Soriano J Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption Science 285 103 106 1999 10.1126/science.285.5424.103 10390358
22 Konrad M Schaller A Seelow D Pandey AV Waldegger S Lesslauer A Vitzthum H Suzuki Y Luk JM Becker C Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement Am J Hum Genet 79 949 957 2006 10.1086/508617 17033971
23 Riedhammer KM Stockler S Ploski R Wenzel M Adis-Dutschmann B Ahting U Alhaddad B Blaschek A Haack TB Kopajtich R De novo stop-loss variants in CLDN11 cause hypomyelinating leukodystrophy Brain 144 411 419 2021 10.1093/brain/awaa410 33313762
24 Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 513 202 209 2014 10.1038/nature13480 25079317
25 Nakayama I Shinozaki E Sakata S Yamamoto N Fujisaki J Muramatsu Y Hirota T Takeuchi K Takahashi S Yamaguchi K Noda T Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults Cancer Sci 110 1352 1363 2019 10.1111/cas.13967 30771244
26 Morin PJ Claudin proteins in human cancer: Promising new targets for diagnosis and therapy Cancer Res 65 9603 9606 2005 10.1158/0008-5472.CAN-05-2782 16266975
27 Sahin U Koslowski M Dhaene K Usener D Brandenburg G Seitz G Huber C Türeci O Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development Clin Cancer Res 14 7624 7634 2008 10.1158/1078-0432.CCR-08-1547 19047087
28 Turksen K Troy TC Junctions gone bad: Claudins and loss of the barrier in cancer Biochim Biophys Acta 1816 73 79 2011 21515339
29 Qu H Jin Q Quan C CLDN6: From traditional barrier function to emerging roles in cancers Int J Mol Sci 22 13416 2021 10.3390/ijms222413416 34948213
30 Roehlen N Muller M Nehme Z Crouchet E Jühling F Del Zompo F Cherradi S Duong FHT Almeida N Saviano A Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment J Hepatol 78 343 355 2023 10.1016/j.jhep.2022.10.011 36309131
31 Katoh M Katoh M Precision medicine for human cancers with Notch signaling dysregulation (Review) Int J Mol Med 45 279 297 2020 31894255
32 Cao W Xing H Li Y Tian W Song Y Jiang Z Yu J Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy Biomark Res 10 38 2022 10.1186/s40364-022-00385-1 35642043
33 Vonniessen B Tabariès S Siegel PM Antibody-mediated targeting of Claudins in cancer Front Oncol 14 1320766 2024 10.3389/fonc.2024.1320766 38371623
34 Nakayama I Qi C Chen Y Nakamura Y Shen L Shitara K Claudin 18.2 as a novel therapeutic target Nat Rev Clin Oncol 21 354 369 2024 10.1038/s41571-024-00874-2 38503878
35 Miwa N Furuse M Tsukita S Niikawa N Nakamura Y Furukawa Y Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers Oncol Res 12 469 476 2001 10.3727/096504001108747477 11939410
36 Katoh M Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β-catenin signaling activation (Review) Int J Mol Med 42 713 725 2018 29786110
37 Zeisel MB Dhawan P Baumert TF Tight junction proteins in gastrointestinal and liver disease Gut 68 547 561 2019 10.1136/gutjnl-2018-316906 30297438
38 Bhat AA Syed N Therachiyil L Nisar S Hashem S Macha MA Yadav SK Krishnankutty R Muralitharan S Al-Naemi H Claudin-1, a double-edged sword in cancer Int J Mol Sci 21 569 2020 10.3390/ijms21020569 31952355
39 Hana C Thaw Dar NN Galo Venegas M Vulfovich M Claudins in cancer: A current and future therapeutic target Int J Mol Sci 25 4634 2024 10.3390/ijms25094634 38731853
40 Toso A Teixiera G Zimmermann T Schmitter D Meyer M Muller M Mailly L Baumert T Iacone R 193P CLAUDIN-1 targeting antibodies in solid tumors: From ALE.C04 to CLAUDIN-1 oncology platform Immunooncol Technol 16 Suppl 1 S100305 2022 10.1016/j.iotech.2022.100305
41 Toso A Teixeira G Zimmermann T Gill SG Schmitter D Meyer M Muller M Mailly L Baumert T Manenti L Iacone R Abstract LB284: CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors Cancer Res 83 Suppl 8 LB284 2023 10.1158/1538-7445.AM2023-LB284
42 Rosa K FDA grantsfast track status to ALE.C04 for recurrent or metastatic CLDN1+ HNSCC OncLive 2023 https://www.onclive.com/view/fda-grants-fast-track-status-to-ale-c04-for-recurrent-or-metastatic-cldn1-hnscc
43 Pelster M Marron TU Friend BD Fan A Yang J Spira AI Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4 J Clin Oncol 42 Suppl 16 TPS2670 2024 10.1200/JCO.2024.42.16_suppl.TPS2670
44 Ben-David U Nudel N Benvenisty N Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells Nat Commun 4 1992 2013 10.1038/ncomms2992 23778593
45 Reinhard K Rengstl B Oehm P Michel K Billmeier A Hayduk N Klein O Kuna K Ouchan Y Wöll S An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Science 367 446 453 2020 10.1126/science.aay5967 31896660
46 Kong FE Li GM Tang YQ Xi SY Loong JHC Li MM Li HL Cheng W Zhu WJ Mo JQ Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate Sci Transl Med 13 eabb6282 2021 10.1126/scitranslmed.abb6282 33536280
47 Zhang C Guo C Li Y Liu K Zhao Q Ouyang L Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis Front Cell Dev Biol 9 726656 2021 10.3389/fcell.2021.726656 34409042
48 Du H Yang X Fan J Du X Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review) Mol Med Rep 24 677 2021 10.3892/mmr.2021.12316 34296304
49 Tsang N Veillard N Horsley E Havenith K Janghra N Zeitseva K Oblette C Kirby I Hogg PW Zammarchi F Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6 Cancer Res 84 76 Suppl S3122 2024 10.1158/1538-7445.AM2024-3122
50 Türeci Ö Kreuzberg M Walter K Wöll S Schmitt R Mitnacht-Kraus R Nakajo I Yamada T Sahin U Abstract 882: The anti-claudin 6 antibody, IMAB027, induces antibody-dependent cellular and complement-dependent cytotoxicity in claudin 6-expressing cancer cells Cancer Res 78 Suppl 13 S882 2018 10.1158/1538-7445.AM2018-882
51 Sahin U Jaeger D Marme F Mavratzas A Krauss J De Greve J Vergote I Tureci O First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part J Clin Oncol 33 15 Suppl S5537 2015 10.1200/jco.2015.33.15_suppl.5537
52 Adra N Vaughn DJ Einhorn LH Hanna NH Funt SA Rosales M Arozullah A Feldman DR A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors Invest New Drugs 40 1087 1094 2022 10.1007/s10637-022-01276-w 35759134
53 McDermott MSJ O'Brien NA Hoffstrom B Gong K Lu M Zhang J Luo T Liang M Jia W Hong JJ Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors Clin Cancer Res 29 2131 2143 2023 10.1158/1078-0432.CCR-22-2981 36884217
54 Konecny GE Wahner Hendrickson AE Winterhoff B Machado A Chander C Davenport S Bilic S Miller LL Chung A Press MF 756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 Ann Oncol 34 Suppl 2 S517 2023 10.1016/j.annonc.2023.09.1935
55 Pham E Henn A Sable B Wahl J Conner K Matthes K Gupta S Yabut R Aeffner F Wilson KL Abstract 5202: AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer Cancer Res 82 Suppl 12 S5202 2022 10.1158/1538-7445.AM2022-5202
56 Stadler CR Ellinghaus U Fischer L Bähr-Mahmud H Rao M Lindemann C Chaturvedi A Scharf C Biermann I Hebich B Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6 Sci Transl Med 16 eadl2720 2024 10.1126/scitranslmed.adl2720 38776391
57 Faber MS Lee SH Kim YK Qi J Avery KN Nguyen DHT Rashid R Eivazi A Chu SY Diaz JE Abstract 1860: Bispecific claudin-6 x CD3 antibodies in a 2 + 1 format demonstrate selectivity and activity on human ovarian cancer cells Cancer Res 81 Suppl 13 S1860 2021 10.1158/1538-7445.AM2021-1860
58 Kamikawa T Kimura N Ishii S Muraoka M Taniguchi K Uchikawa R Yoshimoto M Okuda-Miura M Akai S Kodama T 1172 SAIL66, a next generation of T cell engager targeting CLDN6, potentiates efficacy J Immunother Cancer 11 Suppl 1 S1172 2023
59 Mackensen A Haanen JBAG Koenecke C Alsdorf W Wagner-Drouet E Borchmann P Heudobler D Ferstl B Klobuch S Bokemeyer C CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial Nat Med 29 2844 2853 2023 10.1038/s41591-023-02612-0 37872225
60 Li J Hu H Lian H Yang S Liu M He J Cao B Chen D Hu Y Zhi C NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer Int J Biol Sci 20 1578 1601 2024 10.7150/ijbs.88539 38481806
61 Micke P Mattsson JSM Edlund K Lohr M Jirström K Berglund A Botling J Rahnenfuehrer J Marincevic M Pontén F Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer Int J Cancer 135 2206 2214 2014 10.1002/ijc.28857 24710653
62 Dottermusch M Krüger S Behrens HM Halske C Röcken C Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: Results from a large Caucasian cohort study Virchows Arch 475 563 571 2019 10.1007/s00428-019-02624-7 31332522
63 Chen J Xu Z Hu C Zhang S Zi M Yuan L Cheng X Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications Front Oncol 13 1132319 2023 10.3389/fonc.2023.1132319 36969060
64 Lyu SI Fretter C Simon AG Spielmann SM Damanakis AI Zhao Y Bruns CJ Schmidt T Popp FC Waldschmidt D Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma-real-world evidence Transl Oncol 47 102044 2024 10.1016/j.tranon.2024.102044 38917592
65 Li J Pan H Liu T Xu N Zhang Y Qin Y Shi J Liao D Shen L Luo S A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors J Clin Oncol 41 Suppl 4 S391 2023 10.1200/JCO.2023.41.4_suppl.391
66 Zhang M Gong J Wang J Shi J Zhu H Wang Y Chen Y Wang F Qu X Yu J A phase I/II study of ASKB589 [anti-claudin 18.2 (CLDN18.2) monoclonal antibody] in patients with solid tumors J Clin Oncol 41 Suppl 4 S397 2023 10.1200/JCO.2023.41.4_suppl.397
67 Peng Z Shen L He Y Chen J Hickingbottom B Lu J A phase Ib/II study of ASKB589 [anti-Claudin 18.2 (CLDN18.2) monoclonal antibody] combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma J Clin Oncol 42 Suppl 3 S317 2024 10.1200/JCO.2024.42.3_suppl.317
68 Jin Z Zhang Y Liu F Zhang S Gong J Zhang M Liang X Wang J Li Y Yang X FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study J Clin Oncol 42 Suppl 16 S4142 2024 10.1200/JCO.2024.42.16_suppl.4142
69 Huang J Zhang B Wang Y Wang F Yu Z Wu S Zheng Y Cao Y Xu J Lan D Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial J Clin Oncol 41 Suppl 4 S798 2023 10.1200/JCO.2023.41.4_suppl.798
70 Janjigian Y Tolcher A Mehta R Cecchini M Van Tine B Kundranda M Olatunji A Patel MR Berlin J Rocha-Lima CMSP Abstract CT132: A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors Cancer Res 84 Suppl 7 CT132 2024 10.1158/1538-7445.AM2024-CT132
71 Zhang X Guo Z Zhang J Guo W Sun M Xu N Qi C Zhu X Zhang L Qian X First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study J Clin Oncol 42 Suppl 16 S4048 2024 10.1200/JCO.2024.42.16_suppl.4048
72 Sharma S Starodub A Xu N Chaudhry A Sun M Pelster M Fu Y Zhang X Huang Z Liu W Hsu K Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors J Clin Oncol 41 Suppl 16 S2537 2023 10.1200/JCO.2023.41.16_suppl.2537
73 Türeci O Sahin U Schulze-Bergkamen H Zvirbule Z Lordick F Koeberle D Thuss-Patience P Ettrich T Arnold D Bassermann F A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: The MONO study Ann Oncol 30 1487 1495 2019 10.1093/annonc/mdz199 31240302
74 Shitara K Lordick F Bang YJ Enzinger P Ilson D Shah MA Van Cutsem E Xu RH Aprile G Xu J Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial Lancet 401 1655 1668 2023 10.1016/S0140-6736(23)00620-7 37068504
75 Shah MA Shitara K Ajani JA Bang YJ Enzinger P Ilson D Lordick F Van Cutsem E Gallego Plazas J Huang J Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial Nat Med 29 2133 2141 2023 10.1038/s41591-023-02465-7 37524953
76 Ra J FDA denies approval for Astellas' investigational gastric cancer drug Pharmaceutical Technology 2014 https://www.pharmaceutical-technology.com/news/fda-denies-approval-for-astellas-investigational-gastric-cancer-drug/
77 Conroy R FDA acknowledges zolbetuximab BLA resubmission for CLDN18.2+ gastric cancer CancerNetwork 2024 https://www.cancernetwork.com/view/fda-acknowledges-zolb-etuximab-bla-resubmission-for-cldn18-2-gastric-cancer/
78 Bishnoi S Cao D Mendis SR Coward J Zhao J Xie H Zheng L An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH) J Clin Oncol 42 Suppl 16 S3032 2024 10.1200/JCO.2024.42.16_suppl.3032
79 Xu RH Ruan DY Zhang DS Liu FR Luo SX Zhuang ZX Wang ZN Liu FN Zhang YQ Yang JW A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer J Clin Oncol 41 Suppl 36 S434420 2023 10.1200/JCO.2023.41.36_suppl.434420
80 Raufi AG Goyal L Smyth E Szekeres P Petrone M Hobson R Thress K Origuchi M Nehra J Brown JS CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors J Clin Oncol 42 Suppl 16 TPS3163 2024 10.1200/JCO.2024.42.16_suppl.TPS3163
81 Wang Y Gong J Lin R Zhao S Wang J Wang Q Zhang Y Su D Zhang J Dong Q First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors J Clin Oncol 41 Suppl 16 S3016 2023 10.1200/JCO.2023.41.16_suppl.3016
82 Yu X Zhang J Tazbirkova A Yang J Yue J Sun Y Pan Y Sun M Qin Y Shen L Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study J Clin Oncol 42 Suppl 16 S3037 2024 10.1200/JCO.2024.42.16_suppl.3037
83 Huang W Li Y Liu Z Rodon L Correia S Li Y Li R Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors Eur J Cancer 174 Suppl 1 S41 S42 2022 10.1016/S0959-8049(22)00911-X
84 Bai C Xue J Zheng Y Sun M Ying J Zhou F Yu Y Sun Y Xing L Zhang Y A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer J Clin Oncol 42 Suppl 16 S3028 2024 10.1200/JCO.2024.42.16_suppl.3028
85 Spisek R 2P SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression ESMO Open 8 1 Suppl 2 S101196 2023 10.1016/j.esmoop.2023.101196
86 Rosa K CMG901 elicits responses in CLDN18.2-expressing gastric/GEJ cancer OncLive 2023 https://www.onclive.com/view/cmg901-elicits-responses-in-cldn18-2-expressing-gastric-gej-cancer/
87 Wahner A IBI343 receives FDA fast track designation for advanced/metastatic PDAC OncLive 2024 https://www.onclive.com/view/ibi343-receives-fda-fast-track-designation-for-advanced-metastatic-pdac/
88 Gaspar M Natoli M Castan L Rahmy S Kelton C Mulgrew K Korade M Huhn O Rees DG Sigurdardottir A 1169 AZD5863: A specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing J Immunother Cancer 11 Suppl 1 S1169 2023
89 Gao J Wang Z Jiang W Zhang Y Meng Z Niu Y Sheng Z Chen C Liu X Chen X CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation J Immunother Cancer 11 e006704 2023 10.1136/jitc-2023-006704 37364935
90 Xu Y Fu J Henderson M Lee F Jurcak N Henn A Wahl J Shao Y Wang J Lyman M CLDN18.2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer Gastroenterology 165 1219 1232 2023 10.1053/j.gastro.2023.06.037 37507075
91 Zheng L Ruihong D Jieer Y Xu Q Guo Z Hu C Sun Y Niu Z Hao J Zhang M Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study J Clin Oncol 42 Suppl 16 S2519 2024 10.1200/JCO.2024.42.16_suppl.2519
92 Wang J Dong T Gong X Li D Sun J Luo Y Wu H Safety and pharmacokinetic assessment of the FIC CLDN18.2/4-1BB bispecific antibody in rhesus monkeys Int J Toxicol 43 291 300 2024 10.1177/10915818231221282 38115178
93 Guo Y Wu L Li Y Wen J Xue J Wang Z Li P Zhao W Liu J Rao X First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors J Clin Oncol 42 Suppl 16 S2662 2024 10.1200/JCO.2024.42.16_suppl.2662
94 Overman MJ Melhem R Blum-Murphy MA Ramos C Petrosyan L Li J Perer JK Zou H Wang M Wright HM A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas J Clin Oncol 41 Suppl 4 TPS765 2023 10.1200/JCO.2023.41.4_suppl.TPS765
95 Yk W Gong J Sun Y Zhang J Ni S Hou J Chen X Wang Y Yu Q Qu X Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors J Clin Oncol 41 Suppl 4 S382 2023 10.1200/JCO.2023.41.4_suppl.382
96 Wang Y Gong J Sun Y Yang S Zhang M Cui J Lv J Su H Wang J Lu J 132P A phase I clinical trial of QLS31905 in advanced solid tumors Immunooncol Technol 20 Suppl S100604 2023 10.1016/j.iotech.2023.100604
97 Klein C Brinkmann U Reichert JM Kontermann RE The present and future of bispecific antibodies for cancer therapy Nat Rev Drug Discov 23 301 319 2024 10.1038/s41573-024-00896-6 38448606
98 Goebeler ME Stuhler G Bargou R Bispecific and multispecific antibodies in oncology: Opportunities and challenges Nat Rev Clin Oncol 21 539 560 2024 10.1038/s41571-024-00905-y 38822215
99 Tucker N FDA grants orphan drug designation to TJ-CD4B for gastric cancer Targeted Oncology 2022 https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-tj-cd4b-for-gastric-cancer/
100 Jiang H Shi Z Wang P Wang C Yang L Du G Zhang H Shi B Jia J Li Q Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer J Natl Cancer Inst 111 409 418 2019 10.1093/jnci/djy134 30203099
101 Qi C Liu C Gong J Liu D Wang X Zhang P Qin Y Ge S Zhang M Peng Z Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results Nat Med 30 2224 2234 2024 10.1038/s41591-024-03037-z 38830992
102 Zhen DB Thota R del Corral C Geng D Yang T Wang C Amato G Akram M Miller DS Bubuteishvili-Pacaud L Gibson M A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma J Clin Oncol 41 Suppl 4 TSP480 2023 10.1200/JCO.2023.41.4_suppl.TPS480
103 Luo T Lu Z Zheng R Zhou J Wang S Hao R Sun M Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors J Clin Oncol 42 Suppl 16 e16012 2024 10.1200/JCO.2024.42.16_suppl.e16012
104 Britton Z Breen S Carrasco R Clark B Broggi MAS Lapointe JM Giraldo N Rao Attili BMN Hatke A Grigoriadou C 235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers J Immunother Cancer 11 Suppl 1 A1 A1731 2023
105 Xu H Li W Lv H Gu D Wei X Dai H Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer J Clin Oncol 40 Suppl 16 S4030 2022 10.1200/JCO.2022.40.16_suppl.4030
106 Paul S Konig MF Pardoll DM Bettegowda C Papadopoulos N Wright KM Gabelli SB Ho M van Elsas A Zhou S Cancer therapy with antibodies Nat Rev Cancer 24 399 426 2024 10.1038/s41568-024-00690-x 38740967
107 Fu Z Li S Han S Shi C Zhang Y Antibody drug conjugate: the 'biological missile' for targeted cancer therapy Signal Transduct Target Ther 7 93 2022 10.1038/s41392-022-00947-7 35318309
108 Fuentes-Antrás J Genta S Vijenthira A Siu LL Antibody-drug conjugates: In search of partners of choice Trends Cancer 9 339 354 2023 10.1016/j.trecan.2023.01.003 36746689
109 Kalinsky K Diamond JR Vahdat LT Tolaney SM Juric D O'Shaughnessy J Moroose RL Mayer IA Abramson VG Goldenberg DM Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: Final results from a phase I/II, single-arm, basket trial Ann Oncol 31 1709 1718 2020 10.1016/j.annonc.2020.09.004 32946924
110 Rosenberg J Sridhar SS Zhang J Smith D Ruether D Flaig TW Baranda J Lang J Plimack ER Sangha R EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma J Clin Oncol 38 1041 1049 2020 10.1200/JCO.19.02044 32031899
111 Park K Haura EB Leighl NB Mitchell P Shu CA Girard N Viteri S Han JY Kim SW Lee CK Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study J Clin Oncol 39 3391 3402 2021 10.1200/JCO.21.00662 34339292
112 Fayette J Clatot F Brana I Saada E van Herpen CML Mazard T Perez CA Tabernero J Le Tourneau C Hollebecque A Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study J Clin Oncol 42 Suppl 16 S6014 2024 10.1200/JCO.2024.42.16_suppl.6014
113 Schram AM Goto K Kim DW Martin-Romano P Ou SHI O'Kane GM O'Reilly EM Umemoto K Duruisseaux M Neuzillet C Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers J Clin Oncol 40 Suppl 16 S105 2022 10.1200/JCO.2022.40.16_suppl.105
114 Kim MA Lee HS Lee HE Jeon YK Yang HK Kim WH EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number Histopathology 52 738 746 2008 10.1111/j.1365-2559.2008.03021.x 18397279
115 Van Cutsem E Bang YJ Feng-Yi F Xu JM Lee KW Jiao SC Chong JL López-Sanchez RI Price T Gladkov O HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer Gastric Cancer 18 476 484 2015 10.1007/s10120-014-0402-y 25038874
116 Ahn S Lee J Hong M Kim ST Park SH Choi MG Lee JH Sohn TS Bae JM Kim S FGFR2 in gastric cancer: Protein overexpression predicts gene amplification and high H-index predicts poor survival Mod Pathol 29 1095 1103 2016 10.1038/modpathol.2016.96 27230412
117 Yashiro M Kuroda K Masuda G Okuno T Miki Y Yamamoto Y Sera T Sugimoto A Kushiyama S Nishimura S Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer Sci Rep 11 4698 2021 10.1038/s41598-021-84107-x 33633310
118 Lee HE Kim MA Lee HS Jung EJ Yang HK Lee BL Bang YJ Kim WH MET in gastric carcinomas: Comparison between protein expression and gene copy number and impact on clinical outcome Br J Cancer 107 325 333 2012 10.1038/bjc.2012.237 22644302
119 Katoh M Loriot Y Brandi G Tavolari S Wainberg ZA Katoh M FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions Nat Rev Clin Oncol 21 312 329 2024 10.1038/s41571-024-00869-z 38424198
120 Zhang H Yang Z Zhu X Li J Gao Y Zhang Y Tong Z Fu Q Bao X Li B Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion J Clin Oncol 42 Suppl 16 S3514 2024 10.1200/JCO.2024.42.16_suppl.3514
121 Feng K Guo Y Dai H Wang Y Li X Jia H Han W Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer Sci China Life Sci 59 468 479 2016 10.1007/s11427-016-5023-8 26968708
122 Zhang Q Fu Q Cao W Wang H Xu X Huang J Zou A Zhu J Wan H Yao Y Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 42 Suppl 16 S4019 2024 10.1200/JCO.2024.42.16_suppl.4019
123 Qi C Liu C Li J Gong J Wang X Wang Z Lu X He T Ding Y Wu F Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer J Clin Oncol 42 Suppl 16 S2518 2024 10.1200/JCO.2024.42.16_suppl.2518
124 Neelapu SS Locke FL Bartlett NL Lekakis LJ Miklos DB Jacobson CA Braunschweig I Oluwole OO Siddiqi T Lin Y Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 377 2531 2544 2017 10.1056/NEJMoa1707447 29226797
125 Martin T Usmani SZ Berdeja JG Agha M Cohen AD Hari P Avigan D Deol A Htut M Lesokhin A Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up J Clin Oncol 41 1265 1274 2023 10.1200/JCO.22.00842 35658469
126 Majzner RG Mackall CL Tumor antigen escape from CAR T-cell therapy Cancer Discov 8 1219 1226 2018 10.1158/2159-8290.CD-18-0442 30135176
127 Shah NN Fry TJ Mechanisms of resistance to CAR T cell therapy Nat Rev Clin Oncol 16 372 385 2019 30837712
128 Larson RC Maus MV Recent advances and discoveries in the mechanisms and functions of CAR T cells Nat Rev Cancer 21 145 161 2021 10.1038/s41568-020-00323-z 33483715
129 Hou AJ Chen LC Chen YY Navigating CAR-T cells through the solid-tumour microenvironment Nat Rev Drug Discov 20 531 550 2021 10.1038/s41573-021-00189-2 33972771
130 Tauriello DVF Sancho E Batlle E Overcoming TGFβ-mediated immune evasion in cancer Nat Rev Cancer 22 25 44 2022 10.1038/s41568-021-00413-6 34671117
131 Katoh M Katoh M WNT signaling and cancer stemness Essays Biochem 66 319 331 2022 10.1042/EBC20220016 35837811
132 Gumber D Wang LD Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion EBioMedicine 77 103941 2022 10.1016/j.ebiom.2022.103941 35301179
133 Chan JD Scheffler CM Munoz I Sek K Lee JN Huang YK Yap KM Saw NYL Li J Chen AXY FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy Nature 629 201 210 2024 10.1038/s41586-024-07242-1 38600376
134 Doan AE Mueller KP Chen AY Rouin GT Chen Y Daniel B Lattin J Markovska M Mozarsky B Arias-Umana J FOXO1 is a master regulator of memory programming in CAR T cells Nature 629 211 218 2024 10.1038/s41586-024-07300-8 38600391
